RA Capital Management’s Achillion Pharmaceuticals ACHN Stock Holding History

RA Capital Management’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-2,500,000	Closed	-$30.6M	–	60
2014 Q4	$30.6M	Sell	2,500,000 -500,000	-17%	-$6.11M	3.29%	10
2014 Q3	$29.9M	Hold	3,000,000	–	–	3.54%	9
2014 Q2	$22.7M	Hold	3,000,000	–	–	2.3%	12
2014 Q1	$9.87M	Hold	3,000,000	–	–	0.71%	27
2013 Q4	$9.96M	Sell	3,000,000 -2,500,000	-45%	-$7.25M	1.16%	22
2013 Q3	$16.6M	Buy	5,500,000 +3,500,000	+175%	+$24M	1.73%	19
2013 Q2	$16.4M	Buy	+2,000,000	New	+$15.3M	2.17%	17

Other funds holding ACHN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RA Capital Management's ACHN Position: Q1 2018 in Review

RA Capital Management sold out of Achillion Pharmaceuticals (ACHN) in Q1 2018, closing a stake of 585,890 shares — an estimated $1.69M sold.

RA Capital Management first reported a position in ACHN in Q2 2013 and held it in 19 quarters. The position peaked at $170M in Q2 2014. 127 funds tracked by Wall St. Rank hold ACHN as of Q1 2018.

RA Capital Management reported no remaining Achillion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
RA Capital Management sold 585,890 Achillion Pharmaceuticals shares in Q1 2018, an estimated $1.69M.
RA Capital Management first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 19 quarters.
RA Capital Management's Achillion Pharmaceuticals position peaked at $170M in Q2 2014.
127 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2018.

Based on RA Capital Management's 13F filing for Q1 2018, filed 15 May 2018.